Abstract | BACKGROUND: An association between cancer and increased blood coagulation has been observed for many years. Generally, there is an equilibrium between the coagulation system ( fibrin deposition) and the fibrinolytic system (degradation of fibrin by enzymes). However, in malignant disease such as ovarian carcinoma, this equilibrium is disrupted, resulting in the abnormal activation of coagulation or hypercoagulability. Also, evidence indicates that various components of these pathways may contribute to the disorderly characteristics of malignancy, such as proliferation, invasion, and metastasis. PURPOSE: METHODS: RESULTS: CONCLUSIONS: IMPLICATIONS:
|
Authors | L R Zacharski, V A Memoli, D L Ornstein, S M Rousseau, W Kisiel, B J Kudryk |
Journal | Journal of the National Cancer Institute
(J Natl Cancer Inst)
Vol. 85
Issue 15
Pg. 1225-30
(Aug 04 1993)
ISSN: 0027-8874 [Print] United States |
PMID | 8331683
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Blood Coagulation Factors
- Urokinase-Type Plasminogen Activator
|
Topics |
- Blood Coagulation Factors
(analysis)
- Carcinoma
(metabolism)
- Cystadenocarcinoma
(metabolism)
- Female
- Humans
- Immunoenzyme Techniques
- Ovarian Neoplasms
(enzymology, metabolism)
- Urokinase-Type Plasminogen Activator
(analysis)
|